Your session is about to expire
← Back to Search
Laser Therapy
Thulium Fiber vs MOSES Holmium Laser for Enlarged Prostate
N/A
Recruiting
Led By Hazem Elmansy, MD
Research Sponsored by Thunder Bay Regional Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
History of urethral stenosis or its management
Prostate size < 80 mL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1,3,6,12 months post-op
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two laser treatments for men with an enlarged prostate. These treatments aim to remove excess prostate tissue with less bleeding and faster recovery than traditional methods. One treatment uses a Thulium laser, while the other uses a Holmium laser.
Who is the study for?
This trial is for men over 50 with severe urinary symptoms from an enlarged prostate (BPH) who haven't improved with medication. They must have a prostate size of ≥80 ml, be able to follow study procedures, and give informed consent in English. Men with urethral stenosis history, prostate cancer, active infections or previous BPH surgery are excluded.
What is being tested?
The study compares two laser treatments for BPH: Thulium Fiber Laser (TFL) enucleation and Holmium MOSES Laser enucleation. It aims to see if they're equally effective in reducing hospital stay time and improving intraoperative and postoperative outcomes.
What are the potential side effects?
Potential side effects may include bleeding requiring blood transfusion, late postoperative bleeding similar to TURP complications but expected less due to the nature of laser treatments which typically result in minimal blood loss.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had urethral stenosis or treatment for it.
Select...
My prostate is smaller than 80 mL.
Select...
I have had surgery for an enlarged prostate.
Select...
I have a history of prostate cancer.
Select...
I have bladder control issues due to nerve problems.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1,3,6,12 months post-op
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1,3,6,12 months post-op
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change in size
International Prostate Symptom Score
Operative time
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Thulium Fibre Laser (TFL)Experimental Treatment1 Intervention
Patients randomized to this arm will undergo treatment using the TFL.
Group II: MOSES Holmium LaserExperimental Treatment1 Intervention
Patients randomized to this arm will undergo treatment using the MOSES Holmium laser.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Thulium Fibre Laser
2022
N/A
~190
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Laser-based treatments for an enlarged prostate, such as Thulium Fiber Laser Enucleation (ThuFLEP) and Holmium Laser Enucleation of the Prostate (HoLEP), utilize high-energy lasers to precisely remove excess prostate tissue. These lasers create a vaporization bubble that destroys prostatic tissue with minimal deep tissue penetration, reducing the risk of bleeding and other complications.
ThuFLEP, in particular, uses a high wavelength and pulsed mode of action, which allows for efficient and safe enucleation of large prostate volumes. These treatments are significant for BPH patients as they offer minimally invasive options with shorter hospital stays, reduced catheterization times, and lower risks of perioperative bleeding, making them suitable for patients on anticoagulation therapy.
Thulium Fiber Laser Enucleation of the Prostate: Prospective Study of Mid- and Long-Term Outcomes in 1328 Patients.Novel Thulium Fiber Laser for Enucleation of Prostate: A Retrospective Comparison with Open Simple Prostatectomy.Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis.
Thulium Fiber Laser Enucleation of the Prostate: Prospective Study of Mid- and Long-Term Outcomes in 1328 Patients.Novel Thulium Fiber Laser for Enucleation of Prostate: A Retrospective Comparison with Open Simple Prostatectomy.Enucleation of the prostate for benign prostatic hyperplasia thulium laser versus holmium laser: a systematic review and meta-analysis.
Find a Location
Who is running the clinical trial?
Thunder Bay Regional Research InstituteLead Sponsor
8 Previous Clinical Trials
515 Total Patients Enrolled
Thunder Bay Regional Health Research InstituteLead Sponsor
10 Previous Clinical Trials
757 Total Patients Enrolled
Hazem Elmansy, MDPrincipal InvestigatorThunder Bay Regional Health Sciences Centre
4 Previous Clinical Trials
454 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had urethral stenosis or treatment for it.I can understand and consent to the study in English.My prostate is smaller than 80 mL.I am a man over 50 years old.I have had surgery for an enlarged prostate.I have a history of prostate cancer.My prostate was measured to be 80 ml or larger before surgery.I have bladder control issues due to nerve problems.I do not have an active urinary tract infection, or it is being treated.I have been referred to a urologist for ongoing urinary problems due to an enlarged prostate.My condition did not improve with medication alone.
Research Study Groups:
This trial has the following groups:- Group 1: Thulium Fibre Laser (TFL)
- Group 2: MOSES Holmium Laser
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.